Paul Doolan
Research Subjects
Research Interests
Paul Doolan has a total of 178 co-authors. Here are the top co-authors by number of shared publications:
M Testa
Yonsei University
5 shared publicationsG Sharp
Department of Radiation Oncology, Massachusetts General Hospital, Boston
4 shared publications- Gary J. Royle
University College London
4 shared publications H-M Lu
Department of Radiation Oncology, Massachusetts General Hospital, Boston
4 shared publicationsJ Seco
Massachussetts General Hospital, Quebec, Quebec
4 shared publicationsM Dias
Massachussetts General Hospital, Quebec, Quebec
4 shared publications
Latest Publications
- Open Access
- 29 July 2026
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 99 (1187) , 2326-2335
Results of an international survey of SunCHECK Patient users: consensus and benchmark data for plan verification, pre-treatment quality assurance, and in vivo dosimetry tolerances
Objectives: Electronic portal imaging devices (EPID) are well suited to radiotherapy in vivo dosimetry (IVD), but limited guidance remains a barrier to routine clinical use. This SunCHECK (Sun Nuclear Corporation) user survey captured real-world configurations and tolerances for EPID-based patient-specific verification, as well as other aspects of patient-related QA, to establish consensus benchmark data and inform guidance for new and existing users. Methods: A structured survey was distributed to SunCHECK Patient users across the United Kingdom and Europe. Respondents reported current clinical practice for treatment plan verification, patient-specific quality assurance (PSQA), and IVD, including calibration methods, analysis modes, and investigation tolerances. Results: Sixty-four responses were received from 18 countries. Linear accelerator manufacturer, treatment planning algorithm, and level of SunCHECK experience had minimal influence on applied tolerances. Point dose difference is no longer widely used as a pass-fail metric. Most centers use gamma analysis for calibration with global normalization, a 10% threshold, and a 95% pass rate. Plan verification and PSQA are almost universally assessed using gamma criteria of 3%/3 mm with a 95% passing tolerance. IVD tolerances fall into 2 main approaches: gamma criteria of 10%/5 mm for detecting gross errors, and tighter criteria of either 3%/3 mm or 5%/5 mm for identifying smaller, clinically relevant discrepancies. Conclusions: Despite extensive configurability within SunCHECK, there is strong consistency across centers in selected settings and investigation tolerances. These benchmark data provide practical guidance for reviewing and optimizing local configurations. Advances in knowledge: This work provides consensus-based guidance for configuring EPID IVD systems to reliably identify treatment delivery inconsistencies in clinical practice.
- 29 July 2026
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 99 (1187) , 2326-2335
Open AccessResults of an international survey of SunCHECK Patient users: consensus and benchmark data for plan verification, pre-treatment quality assurance, and in vivo dosimetry tolerances
Objectives: Electronic portal imaging devices (EPID) are well suited to radiotherapy in vivo dosimetry (IVD), but limited guidance remains a barrier to routine clinical use. This SunCHECK (Sun Nuclear Corporation) user survey captured real-world configurations and tolerances for EPID-based patient-specific verification, as well as other aspects of patient-related QA, to establish consensus benchmark data and inform guidance for new and existing users. Methods: A structured survey was distributed to SunCHECK Patient users across the United Kingdom and Europe. Respondents reported current clinical practice for treatment plan verification, patient-specific quality assurance (PSQA), and IVD, including calibration methods, analysis modes, and investigation tolerances. Results: Sixty-four responses were received from 18 countries. Linear accelerator manufacturer, treatment planning algorithm, and level of SunCHECK experience had minimal influence on applied tolerances. Point dose difference is no longer widely used as a pass-fail metric. Most centers use gamma analysis for calibration with global normalization, a 10% threshold, and a 95% pass rate. Plan verification and PSQA are almost universally assessed using gamma criteria of 3%/3 mm with a 95% passing tolerance. IVD tolerances fall into 2 main approaches: gamma criteria of 10%/5 mm for detecting gross errors, and tighter criteria of either 3%/3 mm or 5%/5 mm for identifying smaller, clinically relevant discrepancies. Conclusions: Despite extensive configurability within SunCHECK, there is strong consistency across centers in selected settings and investigation tolerances. These benchmark data provide practical guidance for reviewing and optimizing local configurations. Advances in knowledge: This work provides consensus-based guidance for configuring EPID IVD systems to reliably identify treatment delivery inconsistencies in clinical practice.
- Open Access
- 19 June 2026
- Published by Elsevier in Physica Medica
- Vol. 148, 105844
Multi-institutional international investigation of VMAT treatment planning techniques for breast cancer with regional lymph nodes
- 19 June 2026
- Published by Elsevier in Physica Medica
- Vol. 148, 105844
Open AccessMulti-institutional international investigation of VMAT treatment planning techniques for breast cancer with regional lymph nodes
- Open Access
- 25 May 2026
- Published by Elsevier in Physics and Imaging in Radiation Oncology
- Vol. 39, 101006
A multicentre audit of the geometric accuracy and water equivalence of 3D printed thermoplastic objects for use in radiotherapy
- 25 May 2026
- Published by Elsevier in Physics and Imaging in Radiation Oncology
- Vol. 39, 101006
Open AccessA multicentre audit of the geometric accuracy and water equivalence of 3D printed thermoplastic objects for use in radiotherapy
- 9 July 2025
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 70 (14) , 14TR01
IPEM topical report: results of a 2024 UK survey of artificial intelligence in medical physics and clinical engineering
Medical physics and clinical engineering (MPCE) professionals have a critical role in the safe and effective deployment of artificial intelligence (AI) in healthcare, however their attitudes and opinions towards AI are not well understood. A 2024 survey was launched by the Institute of Physics and Engineering in Medicine to UK MPCE professionals to gather information on the current usage of AI, whether it is believed their role will change, if there is any fear about job replacement, the training being conducted, levels of preparedness, concerns about AI introduction, and barriers to AI deployment. A total of 409 responses were received. It was found that AI is widely used (59% of respondents), with wide disparities between disciplines (radiotherapy 76% compared to clinical engineering 37%). Job losses are predicted by 40% of staff, with junior NHS staff more concerned. Nearly 80% of respondents are investing in their own learning, but only 23% know where to look for training resources. Only 10% of the cohort had some prior AI education. Without prior education on AI, only 13% of respondents feel prepared for AI introduction; but this increases by a factor of three with education. Lack of training and knowledge is the major concern and barrier to AI adoption, while lack of a clear AI governance framework was also frequently cited. This survey provides a snapshot of the current status and attitudes of the UK MPCE workforce towards AI and should be used in guiding future efforts in training and education, addressing discipline disparities and overcoming deployment barriers.
- 9 July 2025
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 70 (14) , 14TR01
IPEM topical report: results of a 2024 UK survey of artificial intelligence in medical physics and clinical engineering
Medical physics and clinical engineering (MPCE) professionals have a critical role in the safe and effective deployment of artificial intelligence (AI) in healthcare, however their attitudes and opinions towards AI are not well understood. A 2024 survey was launched by the Institute of Physics and Engineering in Medicine to UK MPCE professionals to gather information on the current usage of AI, whether it is believed their role will change, if there is any fear about job replacement, the training being conducted, levels of preparedness, concerns about AI introduction, and barriers to AI deployment. A total of 409 responses were received. It was found that AI is widely used (59% of respondents), with wide disparities between disciplines (radiotherapy 76% compared to clinical engineering 37%). Job losses are predicted by 40% of staff, with junior NHS staff more concerned. Nearly 80% of respondents are investing in their own learning, but only 23% know where to look for training resources. Only 10% of the cohort had some prior AI education. Without prior education on AI, only 13% of respondents feel prepared for AI introduction; but this increases by a factor of three with education. Lack of training and knowledge is the major concern and barrier to AI adoption, while lack of a clear AI governance framework was also frequently cited. This survey provides a snapshot of the current status and attitudes of the UK MPCE workforce towards AI and should be used in guiding future efforts in training and education, addressing discipline disparities and overcoming deployment barriers.
- 24 June 2025
- Published by Elsevier in Physica Medica
- Vol. 136, 105028
The current practice of volumetric modulated arc therapy for breast cancer in Europe – A survey by the EFOMP VMAT breast working group
- 24 June 2025
- Published by Elsevier in Physica Medica
- Vol. 136, 105028
The current practice of volumetric modulated arc therapy for breast cancer in Europe – A survey by the EFOMP VMAT breast working group
- 5 February 2025
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 70 (4) , 04TR01
IPEM topical report: guidance on 3D printing in radiotherapy
There has been an increase in the availability and utilization of commercially available 3D printers in radiotherapy, with applications in phantoms, brachytherapy applicators, bolus, compensators, and immobilization devices. Additive manufacturing in the form of 3D printing has the advantage of rapid production of personalized patient specific prints or customized phantoms within a short timeframe. One of the barriers to uptake has been the lack of guidance. The aim of this topical review is to present the radiotherapy applications and provide guidance on important areas for establishing a 3D printing service in a radiotherapy department including procurement, commissioning, material selection, establishment of relevant quality assurance, multidisciplinary team creation and training.
- 5 February 2025
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 70 (4) , 04TR01
IPEM topical report: guidance on 3D printing in radiotherapy
There has been an increase in the availability and utilization of commercially available 3D printers in radiotherapy, with applications in phantoms, brachytherapy applicators, bolus, compensators, and immobilization devices. Additive manufacturing in the form of 3D printing has the advantage of rapid production of personalized patient specific prints or customized phantoms within a short timeframe. One of the barriers to uptake has been the lack of guidance. The aim of this topical review is to present the radiotherapy applications and provide guidance on important areas for establishing a 3D printing service in a radiotherapy department including procurement, commissioning, material selection, establishment of relevant quality assurance, multidisciplinary team creation and training.
- 12 September 2023
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 68 (18) , 18TR02
IPEM topical report: guidance for the clinical implementation of online treatment monitoring solutions for IMRT/VMAT
This report provides guidance for the implementation of online treatment monitoring (OTM) solutions in radiotherapy (RT), with a focus on modulated treatments. Support is provided covering the implementation process, from identification of an OTM solution to local implementation strategy. Guidance has been developed by a RT special interest group (RTSIG) working party (WP) on behalf of the Institute of Physics and Engineering in Medicine (IPEM). Recommendations within the report are derived from the experience of the WP members (in consultation with manufacturers, vendors and user groups), existing guidance or legislation and a UK survey conducted in 2020 (Stevens et al 2021). OTM is an inclusive term representing any system capable of providing a direct or inferred measurement of the delivered dose to a RT patient. Information on each type of OTM is provided but, commensurate with UK demand, guidance is largely influenced by in vivo dosimetry methods utilising the electronic portal imager device (EPID). Sections are included on the choice of OTM solutions, acceptance and commissioning methods with recommendations on routine quality control, analytical methods and tolerance setting, clinical introduction and staffing/resource requirements. The guidance aims to give a practical solution to sensitivity and specificity testing. Functionality is provided for the user to introduce known errors into treatment plans for local testing. Receiver operating characteristic analysis is discussed as a tool to performance assess OTM systems. OTM solutions can help verify the correct delivery of radiotherapy treatment. Furthermore, modern systems are increasingly capable of providing clinical decision-making information which can impact the course of a patient’s treatment. However, technical limitations persist. It is not within the scope of this guidance to critique each available solution, but the user is encouraged to carefully consider workflow and engage with manufacturers in resolving compatibility issues.
- 12 September 2023
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 68 (18) , 18TR02
IPEM topical report: guidance for the clinical implementation of online treatment monitoring solutions for IMRT/VMAT
This report provides guidance for the implementation of online treatment monitoring (OTM) solutions in radiotherapy (RT), with a focus on modulated treatments. Support is provided covering the implementation process, from identification of an OTM solution to local implementation strategy. Guidance has been developed by a RT special interest group (RTSIG) working party (WP) on behalf of the Institute of Physics and Engineering in Medicine (IPEM). Recommendations within the report are derived from the experience of the WP members (in consultation with manufacturers, vendors and user groups), existing guidance or legislation and a UK survey conducted in 2020 (Stevens et al 2021). OTM is an inclusive term representing any system capable of providing a direct or inferred measurement of the delivered dose to a RT patient. Information on each type of OTM is provided but, commensurate with UK demand, guidance is largely influenced by in vivo dosimetry methods utilising the electronic portal imager device (EPID). Sections are included on the choice of OTM solutions, acceptance and commissioning methods with recommendations on routine quality control, analytical methods and tolerance setting, clinical introduction and staffing/resource requirements. The guidance aims to give a practical solution to sensitivity and specificity testing. Functionality is provided for the user to introduce known errors into treatment plans for local testing. Receiver operating characteristic analysis is discussed as a tool to performance assess OTM systems. OTM solutions can help verify the correct delivery of radiotherapy treatment. Furthermore, modern systems are increasingly capable of providing clinical decision-making information which can impact the course of a patient’s treatment. However, technical limitations persist. It is not within the scope of this guidance to critique each available solution, but the user is encouraged to carefully consider workflow and engage with manufacturers in resolving compatibility issues.
- Top Cited PapersOpen Access
- 4 August 2023
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 13, 1213068
A clinical evaluation of the performance of five commercial artificial intelligence contouring systems for radiotherapy
Purpose/objective(s): Auto-segmentation with artificial intelligence (AI) offers an opportunity to reduce inter- and intra-observer variability in contouring, to improve the quality of contours, as well as to reduce the time taken to conduct this manual task. In this work we benchmark the AI auto-segmentation contours produced by five commercial vendors against a common dataset.Methods and materials: The organ at risk (OAR) contours generated by five commercial AI auto-segmentation solutions (Mirada (Mir), MVision (MV), Radformation (Rad), RayStation (Ray) and TheraPanacea (Ther)) were compared to manually-drawn expert contours from 20 breast, 20 head and neck, 20 lung and 20 prostate patients. Comparisons were made using geometric similarity metrics including volumetric and surface Dice similarity coefficient (vDSC and sDSC), Hausdorff distance (HD) and Added Path Length (APL). To assess the time saved, the time taken to manually draw the expert contours, as well as the time to correct the AI contours, were recorded.Results: There are differences in the number of CT contours offered by each AI auto-segmentation solution at the time of the study (Mir 99; MV 143; Rad 83; Ray 67; Ther 86), with all offering contours of some lymph node levels as well as OARs. Averaged across all structures, the median vDSCs were good for all systems and compared favorably with existing literature: Mir 0.82; MV 0.88; Rad 0.86; Ray 0.87; Ther 0.88. All systems offer substantial time savings, ranging between: breast 14-20 mins; head and neck 74-93 mins; lung 20-26 mins; prostate 35-42 mins. The time saved, averaged across all structures, was similar for all systems: Mir 39.8 mins; MV 43.6 mins; Rad 36.6 min; Ray 43.2 mins; Ther 45.2 mins.Conclusions: All five commercial AI auto-segmentation solutions evaluated in this work offer high quality contours in significantly reduced time compared to manual contouring, and could be used to render the radiotherapy workflow more efficient and standardized.
- 4 August 2023
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 13, 1213068
Top Cited PapersOpen AccessA clinical evaluation of the performance of five commercial artificial intelligence contouring systems for radiotherapy
Purpose/objective(s): Auto-segmentation with artificial intelligence (AI) offers an opportunity to reduce inter- and intra-observer variability in contouring, to improve the quality of contours, as well as to reduce the time taken to conduct this manual task. In this work we benchmark the AI auto-segmentation contours produced by five commercial vendors against a common dataset.Methods and materials: The organ at risk (OAR) contours generated by five commercial AI auto-segmentation solutions (Mirada (Mir), MVision (MV), Radformation (Rad), RayStation (Ray) and TheraPanacea (Ther)) were compared to manually-drawn expert contours from 20 breast, 20 head and neck, 20 lung and 20 prostate patients. Comparisons were made using geometric similarity metrics including volumetric and surface Dice similarity coefficient (vDSC and sDSC), Hausdorff distance (HD) and Added Path Length (APL). To assess the time saved, the time taken to manually draw the expert contours, as well as the time to correct the AI contours, were recorded.Results: There are differences in the number of CT contours offered by each AI auto-segmentation solution at the time of the study (Mir 99; MV 143; Rad 83; Ray 67; Ther 86), with all offering contours of some lymph node levels as well as OARs. Averaged across all structures, the median vDSCs were good for all systems and compared favorably with existing literature: Mir 0.82; MV 0.88; Rad 0.86; Ray 0.87; Ther 0.88. All systems offer substantial time savings, ranging between: breast 14-20 mins; head and neck 74-93 mins; lung 20-26 mins; prostate 35-42 mins. The time saved, averaged across all structures, was similar for all systems: Mir 39.8 mins; MV 43.6 mins; Rad 36.6 min; Ray 43.2 mins; Ther 45.2 mins.Conclusions: All five commercial AI auto-segmentation solutions evaluated in this work offer high quality contours in significantly reduced time compared to manual contouring, and could be used to render the radiotherapy workflow more efficient and standardized.
- Open Access
- 30 June 2023
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 188, 109774
Deep learning based automated delineation of the intraprostatic gross tumour volume in PSMA-PET for patients with primary prostate cancer
- 30 June 2023
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 188, 109774
Open AccessDeep learning based automated delineation of the intraprostatic gross tumour volume in PSMA-PET for patients with primary prostate cancer
- 15 November 2021
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 66 (22) , 22TR02
IPEM topical report: results of a 2020 UK survey on the use of online treatment monitoring solutions for IMRT/VMAT
Numerous commercial technologies for online treatment monitoring (OTM) in radiotherapy (RT) are currently available including electronic portal imaging device (EPID) in vivo dosimetry (IVD), transmission detectors and log files analysis. Despite this, in the UK there exists limited guidance on how to implement and commission a system for clinical use or information about the resources required to set up and maintain a service. A Radiotherapy Special Interest Group working party, established by Institute of Physics and Engineering in Medicine was formed with a view to reassess the current practice for OTM in the UK and an aim to develop consensus guidelines for the implementation of a system. A survey distributed to Heads of Medical Physics at 71 UK RT departments investigated: availability of OTM in the UK; estimates of workload; clinical implementation; methods of analysis; quality assurance; and opinions on future directions. The survey achieved a 76% response rate and demonstrated that OTM is widely supported in the UK, with 87% of respondents indicating all patients should undergo OTM. EPID IVD (EIVD) was the most popular form of OTM. An active EIVD service was reported by 37% of respondents, with 84% believing it was the optimal solution. This demonstrates a steady increase in adoption since 2012. Other forms of OTM were in use but they had only been adopted by a minority of centres. Financial barriers and the increase of staff workload continue to hinder wider implementation in other centres. Device automation and integration is a key factor for successful future adoption and requires support between treatment machine and OTM manufacturers. The survey has provided an updated analysis on the use of OTM methods across the UK. Future guidance is recommended on commissioning, adoption of local tolerances and root-cause analysis strategies to assist departments intending to implement OTM.
- 15 November 2021
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 66 (22) , 22TR02
IPEM topical report: results of a 2020 UK survey on the use of online treatment monitoring solutions for IMRT/VMAT
Numerous commercial technologies for online treatment monitoring (OTM) in radiotherapy (RT) are currently available including electronic portal imaging device (EPID) in vivo dosimetry (IVD), transmission detectors and log files analysis. Despite this, in the UK there exists limited guidance on how to implement and commission a system for clinical use or information about the resources required to set up and maintain a service. A Radiotherapy Special Interest Group working party, established by Institute of Physics and Engineering in Medicine was formed with a view to reassess the current practice for OTM in the UK and an aim to develop consensus guidelines for the implementation of a system. A survey distributed to Heads of Medical Physics at 71 UK RT departments investigated: availability of OTM in the UK; estimates of workload; clinical implementation; methods of analysis; quality assurance; and opinions on future directions. The survey achieved a 76% response rate and demonstrated that OTM is widely supported in the UK, with 87% of respondents indicating all patients should undergo OTM. EPID IVD (EIVD) was the most popular form of OTM. An active EIVD service was reported by 37% of respondents, with 84% believing it was the optimal solution. This demonstrates a steady increase in adoption since 2012. Other forms of OTM were in use but they had only been adopted by a minority of centres. Financial barriers and the increase of staff workload continue to hinder wider implementation in other centres. Device automation and integration is a key factor for successful future adoption and requires support between treatment machine and OTM manufacturers. The survey has provided an updated analysis on the use of OTM methods across the UK. Future guidance is recommended on commissioning, adoption of local tolerances and root-cause analysis strategies to assist departments intending to implement OTM.